Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell NewsThe authors discuss the current treatment landscape and detail their approach to first-line immunotherapy regimen selection for patients with advanced-stage, driver-negative NSCLC.
[Nature Reviews Clinical Oncology]
7753456 IM7KGJ45 items 1 apa 0 default asc 1 163838 https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-f189c459db88d761fed1d9662e59eaa9%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22IM7KGJ45%22%2C%22library%22%3A%7B%22id%22%3A7753456%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Grant%20et%20al.%22%2C%22parsedDate%22%3A%222021-06-24%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EGrant%2C%20M.%20J.%2C%20Herbst%2C%20R.%20S.%2C%20%26amp%3B%20Goldberg%2C%20S.%20B.%20%282021%29.%20Selecting%20the%20optimal%20immunotherapy%20regimen%20in%20driver-negative%20metastatic%20NSCLC.%20%3Ci%3ENature%20Reviews%20Clinical%20Oncology%3C%5C%2Fi%3E%2C%201%26%23x2013%3B20.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41571-021-00520-1%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41571-021-00520-1%3C%5C%2Fa%3E%20%3Ca%20title%3D%27Cite%20in%20RIS%20Format%27%20class%3D%27zp-CiteRIS%27%20href%3D%27https%3A%5C%2F%5C%2Fwww.stemcellsciencenews.com%5C%2Fwp-content%5C%2Fplugins%5C%2Fzotpress%5C%2Flib%5C%2Frequest%5C%2Frequest.cite.php%3Fapi_user_id%3D7753456%26amp%3Bitem_key%3DIM7KGJ45%27%3ECite%3C%5C%2Fa%3E%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Selecting%20the%20optimal%20immunotherapy%20regimen%20in%20driver-negative%20metastatic%20NSCLC%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20J.%22%2C%22lastName%22%3A%22Grant%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roy%20S.%22%2C%22lastName%22%3A%22Herbst%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%20B.%22%2C%22lastName%22%3A%22Goldberg%22%7D%5D%2C%22abstractNote%22%3A%22The%20treatment%20landscape%20of%20driver-negative%20non-small-cell%20lung%20cancer%20%28NSCLC%29%20is%20rapidly%20evolving.%20Immune-checkpoint%20inhibitors%2C%20specifically%20those%20targeting%20PD-1%20or%20PD-L1%2C%20have%20demonstrated%20durable%20efficacy%20in%20a%20subset%20of%20patients%20with%20NSCLC%2C%20and%20these%20agents%20have%20become%20the%20cornerstone%20of%20first-line%20therapy.%20Approved%20immunotherapeutic%20strategies%20for%20treatment-naive%20patients%20now%20include%20monotherapy%2C%20immunotherapy-exclusive%20regimens%20or%20chemotherapy%5Cu2013immunotherapy%20combinations.%20Decision%20making%20in%20this%20space%20is%20complex%20given%20the%20absence%20of%20head-to-head%20prospective%20comparisons%2C%20although%20a%20thorough%20analysis%20of%20long-term%20efficacy%20and%20safety%20data%20from%20pivotal%20clinical%20trials%20can%20provide%20insight%20into%20the%20optimal%20management%20of%20each%20subset%20of%20patients.%20Indeed%2C%20histological%20subtype%20and%20the%20extent%20of%20tumour%20cell%20PD-L1%20expression%20are%20paramount%20to%20regimen%20selection%2C%20although%20other%20clinicopathological%20factors%20and%20patient%20preferences%20might%20also%20be%20relevant%20in%20certain%20scenarios.%20Finally%2C%20several%20emerging%20biomarkers%20and%20novel%20therapeutic%20strategies%20are%20currently%20under%20investigation%2C%20and%20these%20might%20further%20refine%20the%20current%20treatment%20paradigm.%20In%20this%20Review%2C%20we%20discuss%20the%20current%20treatment%20landscape%20and%20detail%20our%20approach%20to%20first-line%20immunotherapy%20regimen%20selection%20for%20patients%20with%20advanced-stage%2C%20driver-negative%20NSCLC.%22%2C%22date%22%3A%222021-06-24%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41571-021-00520-1%22%2C%22ISSN%22%3A%221759-4782%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.nature.com%5C%2Farticles%5C%2Fs41571-021-00520-1%22%2C%22deleted%22%3A1%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-06-24T17%3A30%3A09Z%22%7D%7D%5D%7D
Grant, M. J., Herbst, R. S., & Goldberg, S. B. (2021). Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC. Nature Reviews Clinical Oncology, 1–20. https://doi.org/10.1038/s41571-021-00520-1 Cite
